TABLE 1.
Cohort patient and tumor characteristicsa
| Characteristic | Cohort (n = 109) n (%) |
|---|---|
|
| |
| Age: years (IQR) | 58.5 (46.5–68) |
| Gender | 48 (44) |
| Female | 61 (56) |
| Male | |
| Race | 1 (0.9) |
| Asian | 1 (0.9) |
| Black | 1 (0.9) |
| Other | 3 (2.8) |
| Unknown | 103 (94.5) |
| White | |
| Ethnicity | 1 (0.9) |
| Hispanic or Latino | 97 (89.0) |
| Not Hispanic or Latino | 11 (10.1) |
| Unknown | |
| Travel distance: miles (IQR) | 76.6 (31–112.1) |
| Tumor location | 14 (12.8) |
| Head or neck | 19 (17.4) |
| Upper extremity | 45 (41.3) |
| Trunk | 31 (28.4) |
| Lower extremity | |
| Breslow depth: mm (IQR) | 2.2 (1.4–4.4) |
| Presence of ulceration | 46 (42.2) |
| Presence of microsatellites | 12(11) |
| No. of positive SLNs | 84 (77.0) |
| 1 | 21 (19.3) |
| 2 | 4 (3.7) |
| 3 | |
| Maximum tumor deposit in positive SLN: mm (IQR) | 1 (0.3–3) |
| Presence of extranodal extension | 7 (6.5) |
| Stage (AJCC 8th ed) | 1 (0.9) |
| 3A | 59 (54.1) |
| 3B | 46 (42.2) |
| 3C | 2 (1.8) |
| 3D | 1 (0.9) |
| Unavailable | |
| Received adjuvant systemic therapy | 62 (56.9) |
IQR Interquartile range, SLN Sentinel lymph node, AJCC American Joint Committee on Cancer
a
Data arepresented as median (IQR) for continuous measures and n (%) for categorical measures